

# Doris M Benbrook

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1247943/publications.pdf>

Version: 2024-02-01

110  
papers

4,863  
citations

159585

30  
h-index

102487

66  
g-index

113  
all docs

113  
docs citations

113  
times ranked

5578  
citing authors

#	ARTICLE	IF	CITATIONS
1	SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 848682.	3.7	5
2	Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3277.	4.1	2
3	Implication of integrins in eptifibatide interference with platelet stimulation of ovarian cancer. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
4	Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7779.	4.1	3
5	Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 302-311.	1.4	25
6	Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity. <i>Cancers</i> , 2021, 13, 1900.	3.7	13
7	Potential of Pharmaceutical Intervention in Platelets and Cancer Positive Feedback Loop. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
8	SHetA2 Increases the Activity of Palbociclib in Cervical Cancer in vitro and in vivo. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
9	Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. <i>Cancers</i> , 2021, 13, 2322.	3.7	11
10	Abstract 1252: The mechanism of the drug, SHetA2, in cervical cancer cells involves growth inhibition, mitochondria damage and release of AIF to cause caspase-independent cell death. , 2021, , .		0
11	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overclock 10 Tf 50,342 9.1 1,430		
12	Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. <i>Cells</i> , 2021, 10, 2996.	4.1	17
13	Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. <i>Cancers</i> , 2021, 13, 6288.	3.7	15
14	Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115244.	3.0	5
15	Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. <i>International Journal of Cancer</i> , 2020, 147, 1086-1097.	5.1	27
16	Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2000-2008.	3.3	2
17	The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. <i>Cancers</i> , 2020, 12, 3135.	3.7	2
18	Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. <i>Cancers</i> , 2020, 12, 1269.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. <i>AAPS Journal</i> , 2020, 22, 51.	4.4	5
20	Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. <i>Cancers</i> , 2020, 12, 1273.	3.7	21
21	Abstract 27: Development of a rat model of atypical endometrial hyperplasia and a vaginal suppository formulation of SHetA2 for chemoprevention studies. , 2020, , .		0
22	Abstract 2840: Development of a model of dihomo-gamma-linolenic acid interference with platelet promotion of ovarian cancer. , 2020, , .		0
23	Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. <i>GeroScience</i> , 2019, 41, 209-227.	4.6	16
24	Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. <i>European Journal of Medicinal Chemistry</i> , 2019, 170, 16-27.	5.5	7
25	Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. <i>Tissue and Cell</i> , 2018, 52, 57-64.	2.2	5
26	Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. <i>Investigational New Drugs</i> , 2018, 36, 561-570.	2.6	7
27	Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. <i>Cancer Letters</i> , 2018, 425, 174-182.	7.2	21
28	Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 638-646.	3.3	14
29	Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 720-732.	5.5	12
30	Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 3179-3186.	3.3	3
31	Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. <i>GeroScience</i> , 2018, 40, 325-336.	4.6	20
32	Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. <i>PLoS ONE</i> , 2018, 13, e0194046.	2.5	12
33	Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 272-280.	4.3	6
34	Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. <i>Oncology Reports</i> , 2017, 37, 2382-2390.	2.6	17
35	Loss of natural killer T cells promotes pancreatic cancer in $\langle scp \rangle LSL \langle /scp \rangle \hat{\text{Kras}} \langle sup \rangle G12D / + \langle /sup \rangle$ mice. <i>Immunology</i> , 2017, 152, 36-51.	4.4	57
36	A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 291-297.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Bioanalytical method development and validation of HPLC/UV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. <i>Journal of Pharmaceutical Technology &amp; Drug Research</i> , 2017, 6, 2.	1.0	6
38	Abstract 1798: Mortalin precursor as potential marker for chemoprevention with SHetA2. , 2017, , .		0
39	Therapeutic options for management of endometrial hyperplasia. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e8.	2.2	140
40	The pro-inflammatory effect of obesity on high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 143, 40-45.	1.4	5
41	Label-Free Real-Time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. <i>Analytical Chemistry</i> , 2016, 88, 3130-3135.	6.5	25
42	Targeting autophagy in cancer management &ndash; strategies and developments. <i>Cancer Management and Research</i> , 2015, 7, 291.	1.9	96
43	Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 209-217.	5.5	12
44	Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes Into Drugs, 2nd Edition. <i>Clinical Infectious Diseases</i> , 2015, 60, 331-332.	5.8	5
45	A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 38-43.	1.4	82
46	Insulin Exerts Direct Effects on Carcinogenic Transformation of Human Endometrial Organotypic Cultures. <i>Cancer Investigation</i> , 2014, 32, 63-70.	1.3	12
47	History of Retinoic Acid Receptors. <i>Sub-Cellular Biochemistry</i> , 2014, 70, 1-20.	2.4	35
48	SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. <i>Investigational New Drugs</i> , 2014, 32, 412-423.	2.6	33
49	Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 11-15.	1.4	44
50	Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. <i>Drug and Chemical Toxicology</i> , 2013, 36, 284-295.	2.3	32
51	Chemoprevention of Colon and Small Intestinal Tumorigenesis in <i>APC<sup>min</sup>/+</i> Mice By SHetA2 (NSC721689) without Toxicity. <i>Cancer Prevention Research</i> , 2013, 6, 908-916.	1.5	27
52	Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer. <i>Journal of Cancer Therapy</i> , 2013, 04, 7-19.	0.4	3
53	A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 356-361.	1.4	19
54	Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2012, 746, 78-88.	1.7	26

#	ARTICLE	IF	CITATIONS
55	Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression. BMC Proceedings, 2012, 6, .	1.6	0
56	A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology, 2011, 121, 455-461.	1.4	48
57	Internal standard-based analysis of microarray data—Analysis of functional associations between HVE-genes. Nucleic Acids Research, 2011, 39, 7881-7899.	14.5	14
58	The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis. Current Cancer Drug Targets, 2011, 11, 586-599.	1.6	38
59	Abstract 1341: Insulin directly induces endometrial cell proliferation and carcinogenesis. , 2011, , .		0
60	NF- $\kappa$ B is involved in SHetA2 circumvention of TNF- $\alpha$ resistance, but not induction of intrinsic apoptosis. Anti-Cancer Drugs, 2010, 21, 297-305.	1.4	15
61	Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology, 2010, 119, 444-450.	1.4	72
62	Synthesis of N-[3,4-Dihydro-4-(acetoxymethyl)-2,2,4-trimethyl-2H-1-benzothioopyran-6-yl]-N $\epsilon$ -(4-nitrophenyl)thiourea and N-[3,4-dihydro-4-(hydroxymethyl)-2,2,4-trimethyl-2H-1-benzothioopyran-6-yl]-N $\epsilon$ -(4-nitrophenyl)thiourea, a Major Metabolite of N-(3,4-Dihydro-2,2,4,4-tetramethyl-2H-1-benzothioopyran-6-yl)-N $\epsilon$ -(4-nitrophenyl)thiourea. Phosphorus, Sulfur, and Silicon: The Elements, 2010, 185, 103-110.	1.6	5
63	Abstract A140: Chemoprevention of familial adenomatous polyposis by a flexible-heteroarotinoid (Flex-Het), SHetA2, in APCMin mice. , 2010, , .		0
64	Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics, 2009, 8, 1227-1238.	4.1	35
65	Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells. Cancer Research, 2009, 69, 6565-6572.	0.9	164
66	Selective Growth Inhibition of Cancer Cells by $\alpha$ -Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor. Pharmacology, 2009, 84, 271-275.	2.2	6
67	Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecologic Oncology, 2009, 115, 438-442.	1.4	17
68	Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs, 2009, 27, 304-318.	2.6	29
69	Metabolism of a sulfur-containing heteroarotinoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 3371-3381.	1.5	25
70	CAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells. Cancer Research, 2008, 68, 5335-5344.	0.9	44
71	Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3556-3565.	4.1	48
72	Gene Expression Analysis of Biological Systems Driving an Organotypic Model of Endometrial Carcinogenesis and Chemoprevention. Gene Regulation and Systems Biology, 2008, 2, GRSB.S344.	2.3	26

#	ARTICLE	IF	CITATIONS
73	Abstract A13: Chemoprevention agent SHetA2 induces G1 arrest through modulation of a biological system driven by Cyclin D1. , 2008, , .		0
74	Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1814-1822.	4.1	88
75	A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007, 105, 508-516.	1.4	90
76	A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2007, 106, 596-603.	1.4	39
77	Heteroarotinoids with Anti-Cancer Activity Against Ovarian Cancer Cells. <i>Open Medicinal Chemistry Journal</i> , 2007, 1, 11-23.	2.4	13
78	Organotypic cultures represent tumor microenvironment for drug testing. <i>Drug Discovery Today: Disease Models</i> , 2006, 3, 143-148.	1.2	6
79	High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 561-569.	2.3	26
80	Promise and problems of translational research. <i>Gynecologic Oncology</i> , 2006, 103, 14-17.	1.4	2
81	Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. <i>American Journal of Pharmacology and Toxicology</i> , 2006, 1, 83-86.	0.7	4
82	Role of AP-1 Antagonism in Growth Inhibition of Cervical Cancer Cell Lines by Retinoids. <i>American Journal of Pharmacology and Toxicology</i> , 2006, 1, 40-47.	0.7	2
83	Retinoids Chemosensitize Ovarian Cancer Cell Lines to Cisplatin Independent of Nuclear Receptors and p53. <i>American Journal of Pharmacology and Toxicology</i> , 2006, 1, 87-93.	0.7	3
84	Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. <i>Gynecologic Oncology</i> , 2005, 97, 142-150.	1.4	6
85	Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. <i>Investigational New Drugs</i> , 2005, 23, 417-428.	2.6	53
86	Synthesis of Flexible Sulfur-Containing Heteroarotinoids That Induce Apoptosis and Reactive Oxygen Species with Discrimination between Malignant and Benign Cells. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 999-1007.	6.4	68
87	Novel Heteroarotinoids as Potential Antagonists of Mycobacterium bovis BCG. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1008-1017.	6.4	45
88	Prevention of Gynecologic Malignancies. , 2004, , 883-919.		0
89	Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7135-7140.	7.1	203
90	The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. <i>Cancer Research</i> , 2003, 63, 3826-32.	0.9	45

#	ARTICLE	IF	CITATIONS
91	Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. <i>Fertility and Sterility</i> , 2002, 78, 596-602.	1.0	21
92	An ELISA method for detection of human antibodies to an immunotoxin. <i>Journal of Pharmacological and Toxicological Methods</i> , 2002, 47, 169-175.	0.7	10
93	Retinoids Enhance Cisplatin-Based Chemoradiation in Cervical Cancer Cells in Vitro. <i>Gynecologic Oncology</i> , 2002, 85, 223-225.	1.4	13
94	Refining Retinoids with Heteroatoms. <i>Mini-Reviews in Medicinal Chemistry</i> , 2002, 2, 277-283.	2.4	19
95	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. <i>Clinical Cancer Research</i> , 2002, 8, 3520-6.	7.0	60
96	Reticulin Expression Demonstrates Hormonal Responsiveness in a Model of Cycling Human Endometrium. <i>Obstetrics and Gynecology</i> , 2001, 97, 25S.	2.4	0
97	The Mechanism of Retinoic Acid Radiosensitization Is Independent of AP-1 Repression in a Cervical Carcinoma Cell Line. <i>Gynecologic Oncology</i> , 1999, 73, 253-256.	1.4	4
98	Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression. <i>Journal of Lower Genital Tract Disease</i> , 1999, 3, 111-115.	1.9	0
99	Optimization and synthesis of (E)-4-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-yl)-1-propenyl]benzoic acid-11-[14C]. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 789-796.	1.0	1
100	Synthesis, Structure-Activity Relationships, and RAR $\beta$ -Ligand Interactions of Nitrogen Heteroarotinoids. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 3602-3614.	6.4	38
101	Heteroarotinoids Inhibit Head and Neck Cancer Cell Lines in Vitro and in Vivo Through Both RAR and RXR Retinoic Acid Receptors. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4434-4445.	6.4	46
102	Complexity, Retinoid-Responsive Gene Networks, and Bladder Carcinogenesis. <i>Advances in Experimental Medicine and Biology</i> , 1999, 462, 449-467.	1.6	13
103	Synthesis and Characterization of Heteroarotinoids Demonstrate Structure Specificity Relationships. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3753-3757.	6.4	22
104	Epidermal Growth Factor Receptor in Vulvar Malignancies and Its Relationship to Metastasis and Patient Survival. <i>Gynecologic Oncology</i> , 1997, 65, 425-429.	1.4	66
105	Biological Assay for Activity and Molecular Mechanism of Retinoids in Cervical Tumor Cells. <i>Gynecologic Oncology</i> , 1997, 66, 114-121.	1.4	16
106	Biologically Active Heteroarotinoids Exhibiting Anticancer Activity and Decreased Toxicity. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3567-3583.	6.4	57
107	Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. <i>Tissue and Cell</i> , 1995, 27, 269-274.	2.2	10
108	Different binding specificities and transactivation of variant CRE's by CREB complexes. <i>Nucleic Acids Research</i> , 1994, 22, 1463-1469.	14.5	144

#	ARTICLE	IF	CITATIONS
109	A new retinoic acid receptor identified from a hepatocellular carcinoma. <i>Nature</i> , 1988, 333, 669-672.	27.8	619
110	Nucleotide sequence of cDNA encoding a novel human thyroid hormone receptor. <i>Nucleic Acids Research</i> , 1987, 15, 9613-9613.	14.5	18